20:17 , Oct 5, 2018 |  BC Week In Review  |  Company News

Blackstone acquiring Clarus; Galakatos to lead PE firm's new life sciences unit

Blackstone (NYSE:BX) will acquire life sciences investment firm Clarus and launch a new unit, Blackstone Life Sciences. Clarus co-founder and Managing Director Nick Galakatos, who will lead the unit, told BioCentury the group intends to...
17:26 , Aug 17, 2018 |  BC Week In Review  |  Financial News

Blackstone investing $400M in Chinese company HEC

Yichang HEC Changjiang Pharmaceutical Co. Ltd. (HKSE:1558) said it will sell $400 million in convertible bonds to Blackstone Group, according to a filing on Hong Kong Exchanges and Clearing Ltd. (HKEX). The bonds will bear...
21:51 , Aug 15, 2018 |  BC Extra  |  Financial News

Blackstone investing $400M in Chinese company HEC

YiChang HEC Changjiang Pharmaceutical Co. Ltd. (HKSE:1558) said it will sell $400 million in convertible bonds to Blackstone Group, according to a filing on Hong Kong Exchanges and Clearing Ltd. (HKEX). The bonds will bear...
07:00 , Oct 13, 2014 |  BioCentury  |  Finance

Sovereign data

Now that investors have injected almost half a billion dollars into NantHealth, one question is whether the subsidiary of NantWorks LLC can ever reach a valuation that justifies its war chest. This month, NantHealth announced...
00:41 , Aug 1, 2014 |  BC Extra  |  Financial News

Catalent raises $871.3 million in NYSE IPO

Catalent Inc. (NYSE:CTLT) raised $871.3 million through the sale of 42.5 million shares at $20.50 in an IPO on the NYSE. The price values the company at $2.4 billion. Earlier this month, the company amended...
23:29 , Jul 18, 2014 |  BC Extra  |  Financial News

Catalent sets terms for NYSE IPO

Catalent Inc. (Somerset, N.J.) said it plans to sell 42.5 million shares at $19-$22 in an IPO on the NYSE. At the $20.50 midpoint, the company would raise $871.3 million and be valued at $2.4...
07:00 , Jun 9, 2014 |  BioCentury  |  Strategy

Guest Commentary: Cost steamroller

At a private meeting for payers and policy makers the other week, the CMO of one of the big PBMs noted that if Gilead Sciences Inc. 's transformational, and transformationally priced, HCV drug Sovaldi sofosbuvir...
01:38 , Jan 25, 2014 |  BC Extra  |  Financial News

Drug delivery play Catalent files for IPO

Catalent Inc. (Somerset, N.J.) filed to raise up to $100 million in an IPO underwritten by Morgan Stanley and JPMorgan. Catalent provides delivery technologies -- including oral, injectable and respiratory delivery technologies -- for drugs,...
07:00 , Apr 15, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) jumped $5.13 (64%) to $13.10 on Thursday after announcing that FDA said existing data, including a single Phase III trial, were sufficient to support an NDA for pimavanserin to...
01:31 , Apr 10, 2013 |  BC Extra  |  Financial News

More rumors of Life Tech bids

New rumors of competing bids for Life Technologies Corp. (NASDAQ:LIFE) surfaced on Tuesday, sending the company up an additional $0.86 to $66.19. Shares of the tools and reagents company have gained 20% since the company...